175 related articles for article (PubMed ID: 34889268)
21. The dosimetric advantages of perirectal hydrogel spacer in men with localized prostate cancer undergoing stereotactic ablative radiotherapy (SABR).
Sturt P; Suh YE; Khoo V
Med Dosim; 2022 Summer; 47(2):173-176. PubMed ID: 35277316
[TBL] [Abstract][Full Text] [Related]
22. Feasibility of and rectal dosimetry improvement with the use of SpaceOAR® hydrogel for dose-escalated prostate cancer radiotherapy.
van Gysen K; Kneebone A; Alfieri F; Guo L; Eade T
J Med Imaging Radiat Oncol; 2014 Aug; 58(4):511-6. PubMed ID: 24580893
[TBL] [Abstract][Full Text] [Related]
23. SpaceOAR Hydrogel Spacer for Reducing Radiation Toxicity During Radiotherapy for Prostate Cancer. A Systematic Review.
Armstrong N; Bahl A; Pinkawa M; Ryder S; Ahmadu C; Ross J; Bhattacharyya S; Woodward E; Battaglia S; Binns J; Payne H
Urology; 2021 Oct; 156():e74-e85. PubMed ID: 34029607
[TBL] [Abstract][Full Text] [Related]
24. Dosimetric and clinical outcomes of SpaceOAR in men undergoing external beam radiation therapy for localized prostate cancer: A systematic review.
Babar M; Katz A; Ciatto M
J Med Imaging Radiat Oncol; 2021 Jun; 65(3):384-397. PubMed ID: 33855816
[TBL] [Abstract][Full Text] [Related]
25. Polyethylene glycol-based hydrogel rectal spacers for prostate brachytherapy: a systematic review with a focus on technique.
Vaggers S; Rai BP; Chedgy ECP; de la Taille A; Somani BK
World J Urol; 2021 Jun; 39(6):1769-1780. PubMed ID: 32840655
[TBL] [Abstract][Full Text] [Related]
26. Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data.
Karsh LI; Gross ET; Pieczonka CM; Aliotta PJ; Skomra CJ; Ponsky LE; Nieh PT; Han M; Hamstra DA; Shore ND
Urology; 2018 May; 115():39-44. PubMed ID: 29174940
[TBL] [Abstract][Full Text] [Related]
27. Dose-escalated radiotherapy to 82 Gy for prostate cancer following insertion of a peri-rectal hydrogel spacer: 3-year outcomes from a phase II trial.
See AW; Bowden P; Wells G; Appu S; Lawrentschuk N; Liodakis P; Pandeli C; Aarons Y; Smyth LML; McKenzie DP
Radiat Oncol; 2022 Jul; 17(1):131. PubMed ID: 35879722
[TBL] [Abstract][Full Text] [Related]
28. [Use of hydrogel as spacer in Denovier's space: optimization of IMRT radiotherapy of localized prostate cancer].
Klotz T; Mathers MJ; Lazar Y; Gagel B
Urologe A; 2013 Dec; 52(12):1690-7. PubMed ID: 23942724
[TBL] [Abstract][Full Text] [Related]
29. The use of hydrogel spacer in men undergoing high-dose prostate cancer radiotherapy: results of a prospective phase 2 clinical trial.
Chao M; Lim Joon D; Khoo V; Lawrentschuk N; Ho H; Spencer S; Chan Y; Tan A; Pham T; Sengupta S; McMillan K; Liu M; Koufogiannis G; Cham CW; Foroudi F; Bolton D
World J Urol; 2019 Jun; 37(6):1111-1116. PubMed ID: 30251049
[TBL] [Abstract][Full Text] [Related]
30. Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy.
Cuccia F; Mazzola R; Nicosia L; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Vitale C; Mantoan B; De Simone A; Sicignano G; Ruggieri R; Cavalleri S; Alongi F
Radiat Oncol; 2020 Jul; 15(1):178. PubMed ID: 32698843
[TBL] [Abstract][Full Text] [Related]
31. Dosimetric implications of an injection of hyaluronic acid for preserving the rectal wall in prostate stereotactic body radiation therapy.
Chapet O; Udrescu C; Tanguy R; Ruffion A; Fenoglietto P; Sotton MP; Devonec M; Colombel M; Jalade P; Azria D
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):425-32. PubMed ID: 24411613
[TBL] [Abstract][Full Text] [Related]
32. SpaceOAR Hydrogel in Dose-escalated Prostate Cancer Radiotherapy: Rectal Dosimetry and Late Toxicity.
Whalley D; Hruby G; Alfieri F; Kneebone A; Eade T
Clin Oncol (R Coll Radiol); 2016 Oct; 28(10):e148-54. PubMed ID: 27298241
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
[TBL] [Abstract][Full Text] [Related]
34. Absorbable hydrogel spacer use in men undergoing prostate cancer radiotherapy: 12 month toxicity and proctoscopy results of a prospective multicenter phase II trial.
Uhl M; Herfarth K; Eble MJ; Pinkawa M; van Triest B; Kalisvaart R; Weber DC; Miralbell R; Song DY; DeWeese TL
Radiat Oncol; 2014 Apr; 9():96. PubMed ID: 24758224
[TBL] [Abstract][Full Text] [Related]
35. Application of Hydrogel Spacer SpaceOAR Vue for Prostate Radiotherapy.
Hadigal SR; Gupta AK
Tomography; 2022 Oct; 8(6):2648-2661. PubMed ID: 36412680
[TBL] [Abstract][Full Text] [Related]
36. Biological effective dose in analysis of rectal dose in prostate cancer patients who underwent a combination therapy of VMAT and LDR with hydrogel spacer insertion.
Zhang H; Wang L; Riegel AC; Antone J; Potters L; Lee L; Cao Y
J Appl Clin Med Phys; 2022 Jun; 23(6):e13584. PubMed ID: 35285578
[TBL] [Abstract][Full Text] [Related]
37. Injection of hydrogel spacer increased maximal intrafractional prostate motion in anterior and superior directions during volumetric modulated arc therapy-stereotactic body radiation therapy for prostate cancer.
Sawayanagi S; Yamashita H; Ogita M; Takenaka R; Nozawa Y; Watanabe Y; Imae T; Abe O
Radiat Oncol; 2022 Feb; 17(1):41. PubMed ID: 35197092
[TBL] [Abstract][Full Text] [Related]
38. Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials.
Jones RT; Hassan Rezaeian N; Desai NB; Lotan Y; Jia X; Hannan R; Kim DWN; Hornberger B; Dubas J; Laine AM; Zelefsky MJ; Timmerman RD; Folkert MR
Med Dosim; 2017 Winter; 42(4):341-347. PubMed ID: 28774760
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
[TBL] [Abstract][Full Text] [Related]
40. SpaceOAR hydrogel distribution and early complications in patients undergoing radiation therapy for prostate cancer.
Yates AH; Power JW; Dempsey PJ; Agnew A; Murphy BD; Moore R; El Bassiouni M; McNicholas MMJ
Br J Radiol; 2023 Dec; 96(1152):20220947. PubMed ID: 37660394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
